Direct-acting antiviral therapy reduces variceal rebleeding and improves liver function in hepatitis C virus-related cirrhosis: A multicenter retrospective cohort study

Table 9 Competing risk analysis for hepatocellular carcinoma development

Variable	Subdistribution HR (95%CI)	P value
DAA treatment	0.50 (0.30-0.85)	0.010
MELD score > 10	1.80 (1.20-2.70)	0.005
Child-Pugh Class B	1.60 (1.10-2.30)	0.015
Platelets < 150 × 10³/μL	1.70 (1.15-2.50)	0.008

A competing risk analysis was performed using the Fine and Gray subdistribution hazard model, with hepatocellular carcinoma development as the primary event and mortality as a competing risk. MELD: Model for end-stage liver disease; DAA: Direct-acting antiviral.